Check out the visual abstract for the March 23/24 NephJC by Elena Cervantes.
Then, check out the visual abstract for the two compared studies - the original published work by Priti Meena and a bonus one just for this chat by Jeff Kott !
Spin the Urine! Then Spin it Again!
Easier to READ full text papers
ISPD Guidelines for PD in Pediatric AKI: the Visual Abstract
Guidelines make for difficult visual abstracts. but Pooja Sanghi does a great job here distilling the essence of them
The ISPD Guidelines for Children with AKI: An Expert Commentary
The Dual Dustat Visual abstracts
UPDATE:
On April 6, 2021 Fibrogen announced that the analysis of the cardiovascular outcomes was adjusted after the data was unblinded. When the data was reanalyzed without this adjustment roxadustat is less impactful. Importantly for this NephJC discussion, the previously impressive MACE and MACE+ advantage for incident dialysis is no longer found. Roxadustat remains non-inferior in all outcomes, though the confidence intervals have widened.
The Incident dialysis visual abstract has been updated to reflect this change.
At their first attempt, the NSMC interns Alicja Rosolowska and Keia Sanderson have created beautiful visual abstract
The Roxadustat Chronicles: A Two-Article NephJC
Pragmatic trials in nephrology: Bridging the gap between efficacy and effectiveness?
World Kidney Day Chat
Treating Asymptomatic Bacteriuria in Kidney Transplant: the Visual Abstract
The Study at a Glance, visual abstract by Anju Yadav
To Treat or Not to Treat: Bacteriuria in Kidney Transplant Recipients
Announcing #NephTrials
AKI Alerts: the Visual Abstract
Another arresting visual abstract from Denisse Arellano:
Alerting AKI and Avoiding Adverse Aftermaths
STARMEN: the Visual Abstract
Omar Taco with a beautiful VA below
Ponticelli still sparkles in Membranous
The Top Nephrology Stories of 2020
Renalism Returns with Remdesivir
Visual abstract for the Remdesivir in AKI study
Thank-you Dhwanil Patel for the excellent visual abstract for this week’s NephJC Chat
Freely Filtered 28: Fidelio with Burgner and Bakris
The Filtrate welcome Drs. Anna Burgner and George Bakris to discuss the breakthrough clinical trial FIDELIO and the non-steroidal aldosteropne antagonist, finerenone.
